乌苯美司联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期临床研究

Clinical Study on Ubenimex Combined with Salmeterol Fluticasone Propionate in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨乌苯美司联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法选取医院2016年5月至2018年6月收治的AECOPD患者126例,按随机数字表法分为治疗组及对照组,各63例。两组患者均予常规AECOPD治疗并吸入沙美特罗替卡松气雾剂(每日2次,每次1吸),治疗组患者加服乌苯美司胶囊(每日3次,每次10 mg),均连续治疗10周。结果治疗组总有效率为92.06%,显著高于对照组的76.19%(P<0.05);与治疗前比较,两组患者治疗后的第1秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1%)及FEV1/用力肺活量(FVC)水平均显著升高,白细胞介素8(IL-8)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)及丙二醛(MDA)水平均显著降低(P<0.05),且治疗组上述指标改善程度均显著优于对照组(P<0.05);治疗组与对照组不良反应发生率相当(1.59%比3.17%,t=0.581,P=0.563>0.05)。结论乌苯美司联合沙美特罗替卡松治疗AECOPD,可调节肺功能、炎性反应及氧化应激水平。

Objective To investigate the clinical efficacy of ubenimex combined with salmeterol fluticasone propionate in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods Totally 126 patients with AECOPD admitted to our hospital from May 2016 to June 2018 were selected and divided into the treatment group and the control group according to the random number table method,63 cases in each group.The patients in the two groups were treated with routine AECOPD treatment and inhalation of Salmeterol Fluticasone Propionate Aerosol(twice a day,1 inhalation each time),on this basis,the patients in the treatment group were treated with Ubenimex Capsules(3 times a day,10 mg/time).Both groups were treated continuously for 10 weeks.Results The total effective rate of the treatment group was 92.06%,which was significantly higher than 76.19% of the control group(P<0.05).Compared with those before treatment,the forced expiratory volume in 1 second(FEV1),FEV1% and FEV1/forced vital capacity(FVC) were significantly increased,while the levels of interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP) and malondialdehyde(MDA) were significantly decreased in the two groups after treatment(P<0.05),and the improvement of the above indexes in the treatment group was significantly better than that in the control group(P<0.05).The incidence of adverse reactions in the treatment group was similar to that in the control group(1.59% vs.3.17%,t=0.581,P=0.563>0.05).Conclusion Ubenimex combined with salmeterol fluticasone propionate in the treatment of AECOPD can regulate pulmonary function,inflammatory response and oxidative stress.